Evon Medics is bridging the gap between advanced medical devices and accessible digital health. We are developing breakthrough, disease-modifying therapies alongside scalable, neuroscience-backed platforms to reverse cognitive decline and build stronger memory habits.
In our recently published, randomized, double-blind, sham-controlled Phase II clinical trial, our proprietary Computerized Olfactory Adaptive Training (COAT) demonstrated unprecedented disease-modifying potential for Mild Cognitive Impairment (MCI):
COAT successfully reversed brain atrophy, driving measurable increases in gray matter volume in the entorhinal cortex and hippocampus—the epicenter of early Alzheimer's pathobiology.
COAT participants achieved a 2.34-unit improvement in Preclinical Alzheimer's Cognitive Composite (PACC) scores compared to the control group.
Based on these structural gains and cognitive improvements, Evon Medics has submitted an application for FDA Breakthrough Device Designation to expedite our pathway to market.
While our specialized medical devices pioneer structural regeneration in clinical populations, MemoryDriver serves as our highly scalable consumer counterpart.
Traditional brain-training apps fail to leverage proven mechanisms of neuroplasticity. MemoryDriver is the first cognitive training app built directly on established navigation neuroscience. Decades of research show that people who frequently navigate complex environments develop stronger and larger hippocampal memory centers. MemoryDriver intentionally structures every interaction to engage these exact spatial memory systems, transforming validated neuroscience into a daily cognitive training experience accessible to everyone.
Since 2018, Evon Medics has secured nearly $14 million in highly competitive, non-dilutive funding from the National Institutes of Health (NIH). This robust institutional backing validates our foundational science and significantly de-risks our pathway to commercialization.
Our track record demonstrates not only the scientific validity of our approaches but our ability to execute complex, multi-year clinical development programs:
~$3.1M for transforming chronic pain management.
~$3.1M for pioneering Alzheimer’s prevention and cognitive restoration.
~$2.9M for the rapid early detection of cognitive decline.
~$2.9M for advancing digital health equity and the remote management of substance use disorders.
~$1.9M for revolutionizing addiction treatment via orbitofrontal cortex training.
Our multidisciplinary team combines decades of expertise in clinical neuroscience, product development, and digital health. Guided by world-class researchers and industry veterans, we are uniquely positioned to bring first-to-market cognitive therapeutics to the global stage.
With a scalable SaaS model, strong market tailwinds, and an active pipeline of Disease-Modifying Therapeutics, Evon Medics is positioned for exponential growth.
EvON Medics team will contact you within 3 business days after receiving an inquiry.
